Speaker: Date: Topic
Marwa Sabe, MD, MPH
Mar. 1, 2016
Pulmonary Hypertension in Left Heart Disease
Responsibility for Content
The PowerPoint presentation, Take-Away points, Objectives, and Abstract links were sent by Medical Library Services and the CME Committee.
Diane E. Young, Information Specialist
Take-Away Points of the Presentation
1. PH due to left heart disease (WHO Group II PH) is the most common cause of PH.
2. PH in LHD is associated with poor outcomes.
3. PH in LHD can be passive or reactive and may be reversible or fixed.
4. Treatment relies mostly on treating the underlying cause of left heart disease.
5. PDE 5 inhibitors and soluble guanylate cyclase activators are safe in these patients and are being investigated for efficacy.
6. PDE 5 inhibitors should be considered in the pre-transplant and post LVAD population.
Objectives of the Presentation
Participants should be able to:
- Define and classify types of pulmonary hypertension and specifically Group II PH.
- Understand the pathophysiology of Group II PH.
- Distinguish pre and post capillary pulmonary hypertension.
- Understand the diagnostic approach for Group II PH.
- Become familiar with different treatment pathways in pulmonary hypertension and specifically for Group II PH.
- Understand how pulmonary hypertension affects advanced heart failure evaluation and therapies.
Links to Abstracts of Articles Cited (contact Diane Young for full-text articles at firstname.lastname@example.org)
PDF of the PowerPoint Presentation
Director of Medical Education and Committee Member have indicated they have no relevant financial interests or relationships to disclose. Faculty has indicated no relevant financial interests or relationships to disclose.